Cancer patients in England will receive a new game-changing therapy treatment under the first negotiated deal of its kind struck in Europe.
An inflammation marker was associated with several unfavorable characteristics in diffuse large B-cell lymphoma.
The frequency of hepatotoxic immune-related adverse events varied in patients receiving one vs multiple chemotherapy agents.
Previous research showed that gefitinib can improve DFS in certain NSCLC patients, raising the possibility that EGFR-targeted TKIs could be beneficial in the neoadjuvant setting.
New research evaluated whether symptomatic indolent follicular lymphoma requires new long-term therapy after first-line rituximab without chemotherapy.
The combo showed improvement in disease-free survival over tamoxifen in premenopausal patients with hormone receptor (HR)-positive early breast cancer.
The findings of this study, recently published in JAMA Oncology, directly contradict previously conducted research on the same topic.
Dr. Filip Janku speaks with Cancer Network about a phase I clinical trial investigating the use of bacterial clostridium novyi-NT in solid tumors.
In this video, Dr. Nancy Davidson highlights current and next-generation diagnostics and therapies in breast cancer, as well as the need for “team science” in clinical trials.
In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.